Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02625623 · ClinicalTrials.gov registry record · Phase 3
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
A Phase 3 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 371
- Enrollment target
NCT02625623 is a Phase 3 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 371 participants.
The verdict
NCT02625623, a Phase 3 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 371 participants
- Enrollment target
Study Summary
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
Interventions
- DRUG Paclitaxel
- DRUG Irinotecan
- DRUG Avelumab
- OTHER Best Supportive Care (BSC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2015-12-28 |
| Est. Completion | 2019-11-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02625623
The ClinicalTrials.gov registry entry for NCT02625623 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 371 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Paclitaxel is the first listed.
NCT02625623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02625623 about?
NCT02625623 is a clinical study titled "Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)". The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
What is the current status of trial NCT02625623?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 371 participants. The study started on 2015-12-28. Estimated completion is 2019-11-13.
What interventions are being tested in trial NCT02625623?
The interventions under investigation include: Paclitaxel (DRUG), Irinotecan (DRUG), Avelumab (DRUG), Best Supportive Care (BSC) (OTHER).
Who is sponsoring clinical trial NCT02625623?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.